Pemetrexed Market Outlook - 2027
Pemetrexed is a chemotherapy for the treatment of pleural mesothelioma and non-small cell lung cancer. In 2004, the Food and Drug Administration approved first pemetrexed for treatment of malignant pleural mesothelioma. Pleural mesothelioma is the type of tumor of the mesothelium, the thin layer of tissue that covers many of the internal organs, in combination with cisplatin. This medicine prepared for patients whose disease is either unrespectable or who are not otherwise candidates for curative surgery. In 2008, the FDA approved pemetrexed as a first-line treatment, in combination with cisplatin, against metastatic non-small cell lung cancer (NSCLC) in patients with non-squamous histology. “Eli Lilly and Company”, was the first who introduce the drug treatment for various forms of cancer. They launched “Alimta” drug for the treatment of types of cancer such as Lung, Liver, Colorectal, Stomach, Breast, and others. Most cancers that start in the lung, known as primary lung cancers, are carcinomas. The two main types are small-cell lung carcinoma (SCLC) and non-small-cell lung carcinoma (NSCLC). Pemetrexed is widely used to treat the non-small lung carcinoma.
COVID-19 Scenario Analysis:
Pharmaceutical and biotech companies together with governments around the globe are working to address the COVID-19 outbreak, from supporting the development of vaccines to planning for medicines supply chain challenges. Currently, around 115 vaccine candidates and 155 molecules are in the R&D pipeline. Moreover, commonly used drugs such as Hydroxychloroquine have witnessed dramatic surge in demand for the management of COVID-19. Such high demand for these drugs has presented huge opportunity for manufacturers of COVID-19 management drugs, as many developed countries are short of these drugs. Owing to the demand for vaccine and treatment drugs for COVID-19, the pharmaceutical and biotechnology industry is expected to witness a significant growth in the future.
As the COVID-19 virus outbreak in December 2019, the disease has spread to almost 100 countries across the globe with the “World Health Organization” announcing it a public health emergency. The global impacts of the COVID-19 pandemic are already starting to be felt, and will significantly affect the pemetrexed market in 2020. COVID-19 can affect the global economy in three main ways by directly affecting production and demand, by creating supply chain and market disruption, and by its financial impact on firms and financial markets.
Top impacting factors: Market Scenario Analysis, Trends, Drivers and Impact Analysis:
Globally, North America contribute the largest market share and dominate the pemetrexed market, due to the increasing incidence of non-small cell lung cancer and presence of major market player. However, Asia- Pacific expected to expand market growth rate due to increasing demand for the treatment of lung cancer, rising incidence of cancer and growing R&D activities
According to WHO, around 7.6 million deaths of patient were found due to the cancer. Cancer is one of the leading cause of death across the globe. More than 70 percent of all cancer deaths occurred in developing countries. “American Cancer Society” reported that in 2017, around 13% of all new cancers are lung cancer. Also reported that lung cancer include both small cell and non-small cell is the second most common type of cancer in U.S. “American Cancer Society” stated that in 2019, around 228,150 new cases of lung cancer would be diagnosed in the U.S. and survival rate for non-small cell lung cancer in stage I.
The factor such as “rising intake of chemotherapy drugs, increasing demand for the treatment associated with cancer, rising Instances of lung cancer. Lung cancer, also known as lung carcinoma, is a malignant lung tumour characterized by uncontrolled cell growth in tissues of the lung, rising government initiative and the presence of favourable government policies, Launch of generic version at low price is expected to rise adoption of the drug, Approval of novel indications of pemetrexed are drive the growth of pemetrexed market. A factor that restrain the growth of the market is the high cost of chemotherapy drug development. The major opportunities available for pemetrexed market includes, increasing R&D activities, introducing new advanced therapy for lung cancer, presence of favourable government initiative, rising investment in R&D, increasing launch of new product
New Product launch to flourish the market:
Major Key market manufacturer have been focusing on increasing research and development activities and producing new product solution for specific applications as there are varying demands based on the utilization. Leading market players have determined how improved accuracy can be influential in many applications. Eli Lilly and Company sold the Pemetrexed, under brand name “Alimta”. It is a chemotherapy drug indicated for the treatment of pleural mesothelioma and non-small cell lung cancer.
In 2004, Eli Lilly and Company received U.S. Food and Drug Administration approval for pemetrexed for treatment of malignant pleural mesothelioma, and in 2008, company received another approval from FDA for “Alimta” is a folate analog metabolic inhibitor and in combinations with certain drugs it is indicated for various diseases. This prescribed for the treatment of advanced and metastatic non-small cell lung cancer.
In 2018, “STADAPHARM GmbH”, has launched “Pemetrexed STADA” a generic version of Alimta in Europe.
In 2018, Eli Lilly and Company received the U.S. Food and Drug Administration (FDA) approval for “Carboplatin and KEYTRUDA” for the l treatment of patients with metastatic nonsquamous non-small cell lung cancer (NSCLC).
In 2017, “Eagle Pharmaceuticals Inc.” has received the U.S. Food and Drug Administration tentative approval for its diluted version of Eli Lilly and Company blockbuster cancer drug Alimta.
Key benefits of the report:
- This study presents the analytical depiction of the global pemetrexed market along with the current trends and future estimations to determine the imminent investment pockets.
- The report presents information related to key drivers, restraints, and opportunities along with detailed analysis of the global pemetrexed market share.
- The current market is quantitatively analyzed to highlight the global pemetrexed market growth scenario.
- Porter’s five forces analysis illustrates the potency of buyers & suppliers in the market.
- The report provides a detailed global pemetrexed market analysis based on competitive intensity and how the competition will take shape in coming years.
Questions answered in the Pemetrexed Market research report:
- Who are the leading market player’s active in pemetrexed market?
- What are the current trends will influence the pemetrexed market in the next few years?
- What are the driving factors, restraints, and opportunities in the market?
- What are the projections for the future that will help in taking further strategic steps?
Pemetrexed Market Report Highlights
| Aspects | Details |
 By Strength |
|
 By Distribution Channel |
|
 By End User |
|
 By Region |
|
 Key Market Players | Eagle Pharmaceuticals, Inc, Abbott Laboratries, FRESENIUS KABI, TEVA PHARMACEUTICAL INDUSTRIES LTD., Pfizer, Biocon, APOTEX, Eli Lilly and Company, Qilu Pharmaceutical, Stada Arzneimittel AG |
Loading Table Of Content...
